(OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its ...

BOSTON, MASSACHUSETTS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat ...

Dr. David Platt, and Andrew Blumenthal. The preprint reviews detailed theories regarding the resistance to ICI therapy and how galectin-3 contributes to resistance. Immune Checkpoint Inhibitors ...

"The magnitude of this breakthrough in cancer research cannot be overstated," said Dr. David Platt, CEO of Bioxytran Inc. "Our findings herald a significant shift in cancer treatment paradigms. We've ...

Galectin Antagonists in Cancer "The magnitude of this breakthrough in cancer research cannot be overstated," said Dr. David Platt, CEO of Bioxytran Inc. "Our findings herald a significant shift in ...

Dr. David Platt, and Andrew Blumenthal. The preprint reviews detailed theories regarding the resistance to ICI therapy and how galectin-3 contributes to resistance. Immune Checkpoint Inhibitors (ICI): ...